克罗恩病患者初次回盲部切除术后预防性用药对长期手术、严重内镜及内镜或影像学复发的影响
荷兰2000-2020年回顾性队列纳入807例初次回盲部切除的克罗恩病患者,36%接受术后预防性用药,中位随访5.0年。预防性用药组手术、严重内镜及内镜或影像学复发率均显著更低,IPTW分析显示严重内镜复发aOR 0.64(95%CI 0.43-0.97),内镜或影像学复发aOR 0.65(95%CI 0.47-0.91)。
要点
- 术后预防性用药与手术、严重内镜及内镜或影像学复发率显著降低相关。
- 多变量分析中预防性用药是严重内镜复发(aHR 0.5)和内镜或影像学复发(aHR 0.6)的保护因素。
- 术后1年内行回结肠镜检查及2010年及以后手术的患者中,保护效应持续存在。
核心结论
- 初次回盲部切除术后预防性用药显著降低克罗恩病长期复发率,并被确定为严重内镜及内镜或影像学复发的保护因素。
研究设计与样本
- 荷兰2000-2020年回顾性队列研究,纳入807例接受初次回盲部切除的克罗恩病患者。
- 按术后12周内是否接受预防性用药分为两组,采用逆概率治疗加权(IPTW)调整混杂和选择偏倚。
- 采用Kaplan-Meier分析和Cox比例风险模型评估预防性用药与结局的关联。
主要发现
- 中位随访5.0年,36%的患者接受术后预防性用药。
- 预防性用药组手术、严重内镜及内镜或影像学复发率均显著更低(p=0.01;p<0.01;p<0.01)。
- IPTW分析显示预防性用药与严重内镜复发风险降低相关(aOR 0.64;95%CI 0.43-0.97)。
- IPTW分析显示预防性用药与内镜或影像学复发风险降低相关(aOR 0.65;95%CI 0.47-0.91)。
- 多变量分析中预防性用药是严重内镜复发(aHR 0.5;95%CI 0.4-0.6)和内镜或影像学复发(aHR 0.6;95%CI 0.5-0.7)的保护因素。
关键数值与推荐
- 严重内镜复发定义为改良Rutgeerts评分(mRS)≥i3。
- 内镜或影像学复发定义为mRS≥i2b或影像学复发。
- 手术复发定义为因克罗恩病再次切除。
- 术后预防性用药定义为回盲部切除术后12周内开始用药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of prophylactic medication following ileocecal resection (ICR) for Crohn's disease (CD) merits further elucidation. Prophylactic medication following ileocecal resection (ICR) is recommended in patients with Crohn's disease (CD), particularly in patients at increased risk of recurrence, but the impact on long-term outcomes needs to be further elucidated. AIM: To evaluate the effect of postoperative prophylactic medication on long-term prognosis. METHODS: A retrospective cohort study was performed in patients with CD who underwent primary ICR between 2000-2020 in the Netherlands. Patients were divided into two groups: postoperative prophylactic medication [< 12 weeks following ICR] versus no postoperative prophylactic medication. Outcomes were surgical recurrence [re-resection for CD], severe endoscopic recurrence [modified Rutgeerts score (mRS) ≥ i3] and endoscopic or radiologic recurrence [mRS ≥ i2b or radiologic recurrence]. Inverse probability of treatment weighting [IPTW] method was used to adjust for confounding and selection bias. Survival and association between postoperative prophylactic medication and outcomes were assessed with Kaplan-Meier analyses and Cox proportional hazard models. RESULTS: 807 patients underwent ICR (median follow-up 5.0 years); 36% received postoperative prophylactic medication. Surgical, severe endoscopic and endoscopic or radiologic recurrence rates were significantly lower in those who received prophylactic medication (p = 0.01; p < 0.01; p < 0.01). IPTW analysis showed a lower risk of severe endoscopic and endoscopic or radiologic recurrence in patients treated with postoperative prophylactic medication (aOR 0.64; 95% CI 0.43-0.97; aOR 0.65; 95% CI 0.47-0.91), which also was identified as a protective factor for severe endoscopic (aHR 0.5; 95% CI 0.4-0.6) and endoscopic or radiologic recurrence (aHR 0.6, 95% CI 0.5-0.7) in multivariable analysis after correction for confounding factors. A comparable protective effect of postoperative prophylactic medication was sustained in patients who underwent ileocolonoscopy <1 year postoperatively and who underwent surgery on or after 2010. CONCLUSIONS: Prophylactic medication following primary ICR significantly reduces long-term recurrence rates in CD and was identified as a protective factor for severe endoscopic and endoscopic or radiologic recurrence.
引用
- Ten Bokkel Huinink S, Bak MTJ, Beelen EMJ, et al. The Impact of Postoperative Prophylactic Medication on Long-Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease. Aliment Pharmacol Ther. 2025. PMID: 39856782. doi:10.1111/apt.18496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。